跳至主要内容
临床试验/NL-OMON26368
NL-OMON26368已完成不适用

The effect of glycopyrroniumbromide on nocturnal clozapine induced sialorrhea in psychiatric patients: A randomized, cross-over, double blind, placebo controlled trial with an extended open label phase (QUITSPIT-study).

Mw. Dr. Ingeborg WiltingziekenhuisapothekerUniversitair Medisch Centrum Utrechtziekenhuisapotheek0 个研究点目标入组 33 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
33

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients using clozapine who are diagnosed with schizophrenia, a schizoaffective disorder or other psychiatric condition meeting DSM-IV criteria;
  • 2. A clozapine dosage that remained unchanged for three months prior to inclusion;

排除标准

  • 1. Known hypersensitivity to glycopyroniumbromide, sorbic acid or saccharine sodium;
  • 2. A comorbidity associated with sialorrhea (Parkinsons disease, cerebral palsy);

研究者

发起方
Mw. Dr. Ingeborg WiltingziekenhuisapothekerUniversitair Medisch Centrum Utrechtziekenhuisapotheek

相似试验

The effect of glycopyrroniumbromide oral solution... | 临床试验